Skip to main content
As published for the week of Monday, December 15, 2014

  • Cover Story: Strategy: Momenta moving on

    Why Momenta abandoning complex generics in favor of novel drugs and biosimilars

    By Catherine Shaffer, Senior Writer

    Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc.'s novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics.

    Momenta was founded in 2001 to develop a platform technology to analyze complex carbohydrate molecules that are beyond the reach of conventional methods of characterization. By using the technology to solve what had been scientifically intractable problems, the company hoped to build a portfolio of complex generics, novel drugs and biosimilars — all of which would be insulated from competition by either IP or know-how created by the platform.

    Full Article

Money Raised in 2014

Last week, the biotech industry raised $820 million, bringing to $52.8 billion the total raised year-to-date. In 2013, a total of $37.1 billion was raised, including $14.4 billion in debt, $10 billion in follow-ons, $2.8 billion in PIPEs and other equity, $3.9 billion in IPOs, and $6 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial